TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15534491

Group type: EXPERIMENTAL
Intervention: HLA-A2-restricted peptide (ESO-1:165V)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-DP4-restricted peptide (NY-ESO-1:161-180)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant vaccination with both peptides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peptide vaccine given daily for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-A2-restricted epitope
Number of subjects: 0
Study: 11464354

Group type: EXPERIMENTAL
Intervention: 150 microg of intraarticular clonidine with subcutaneous saline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 500 microg of intraarticular neostigmine with subcutaneous saline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 150 microg of intraarticular clonidine and 500 microg of neostigmine with subcutaneous saline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 150 microg of intraarticular clonidine with 500 microg of subcutaneous neostigmine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 500 microg of intraarticular neostigmine with 150 microg of subcutaneous clonidine
Number of subjects: 84

Group type: COMPARATOR
Intervention: intraarticular and subcutaneous isotonic saline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 84
Study: 9059319

Group type: EXPERIMENTAL
Intervention: Voluntary isometric contraction (40% of maximum voluntary contraction)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non‐voluntary electrically evoked contractions (40% of maximum voluntary contraction)
Number of subjects: 10
Study: 7893580

Group type: EXPERIMENTAL
Intervention: Didanosine 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg
Number of subjects: 10
Study: 3556193

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol 160 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol 320 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oros oxprenolol 10/170 mg
Number of subjects: 31
Study: 29325557

Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (higher reward for behaviour)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (lower covert restriction)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (increased structured meal timing)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (overt restriction)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (covert restriction)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Family meal setting
Number of subjects: 207
Study: 27333235

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 30
Study: 24363363

Group type: EXPERIMENTAL
Intervention: Amoxicillin dissolved in human milk at a concentration of 50 mg/mL
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amoxicillin dissolved in water at a concentration of 50 mg/mL
Number of subjects: 16
Study: 24373369

Group type: EXPERIMENTAL
Intervention: Mud-bath therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 41
Study: 20035226

Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg kg(‐1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg kg(‐1) + low-dose oral ketamine 2 mg kg(‐1)
Number of subjects: 92
Study: 17600651

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group treatment
Number of subjects: 0
Study: 16815744

Group type: EXPERIMENTAL
Intervention: Zolpidem-MR 12.5mg
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 12815569

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 3091
Study: 10768021

Group type: EXPERIMENTAL
Intervention: 900 cd.m‐2 surround
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 9 cd.m‐2 surround
Number of subjects: 4

Group type: COMPARATOR
Intervention: 3-30 cd.m‐2 surrounds
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Higher luminance surrounds
Number of subjects: 4
Study: 7721443

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (Estraderm-TTS-50) and norethisterone acetate (NETA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no HRT)
Number of subjects: 26
Study: 2707399

Group type: COMPARATOR
Intervention: Oxygen concentrators only (OC)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Small oxygen cylinders plus OC (B1)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Liquid oxygen (B2)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (both groups)
Number of subjects: 159
Study: 17642108

Group type: EXPERIMENTAL
Intervention: High dose lithium chloride (0.72 mEq/kg/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Medium dose lithium chloride (0.5 mEq/kg/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low dose lithium chloride (0.24 mEq/kg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30466310

Group type: EXPERIMENTAL
Intervention: Probabilistic linkage using limited patient identifiers from the Canadian Cancer Trials Group and administrative data from the Institute for Clinical Evaluative Sciences.
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Probabilistic linkage between Canadian Cancer Trials Group data and Institute for Clinical Evaluative Sciences data.
Number of subjects: 293

Group type: COMPARATOR
Intervention: Institute for Clinical Evaluative Sciences data.
Number of subjects: 293

Group type: COMPARATOR
Intervention: Administrative databases during clinical trial conduct.
Number of subjects: 293
Study: 28526329

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention aimed at reducing sedentary time through guided goal setting and behaviour change techniques.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham intervention consisting of weekly phone calls for 6 weeks.
Number of subjects: 70
Study: 25616919

Group type: EXPERIMENTAL
Intervention: 60 mg prasugrel
Number of subjects: 62

Group type: COMPARATOR
Intervention: 600 mg clopidogrel
Number of subjects: 62
Study: 23380072

Group type: EXPERIMENTAL
Intervention: Arginine Mouthwash (0.8% arginine, PVM/MA copolymer, pyrophosphates, and 0.05% sodium fluoride)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Negative Control Mouthwash (ordinary mouthwash without any active ingredients)
Number of subjects: 90
Study: 21784373

Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (1g niacin/20 mg laropiprant) for the first 4 weeks, then 2 tablets once daily thereafter
Number of subjects: 785

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 785
Study: 19160734

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17225939

Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (6.0 Gy total, 1.0 Gy per fraction, 2 fractions per week for 3 weeks)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (3.0 Gy total, 0.5 Gy per fraction, 2 fractions per week)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comparison of response to RT between both groups
Number of subjects: 130
Study: 15452520

Group type: EXPERIMENTAL
Intervention: Lidocaine by iontophoresis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Collaborative procedure
Number of subjects: 90
Study: 11685184

Group type: EXPERIMENTAL
Intervention: Direct stent implantation
Number of subjects: 77
Study: 10933472

Group type: EXPERIMENTAL
Intervention: Multiple sclerosis patients with major mood disorders
Number of subjects: 65

Group type: COMPARATOR
Intervention: Polyneuropathy patients
Number of subjects: 65
Study: 7987192

Group type: EXPERIMENTAL
Intervention: Highly role-specified (HRS) version of the alcohol prevention programme
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Less role-specified (LRS) version of the alcohol prevention programme
Number of subjects: 955

Group type: COMPARATOR
Intervention: Non-treated comparison condition
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Overall programme effect across all dependent variables
Number of subjects: 955
Study: 3540135

Group type: EXPERIMENTAL
Intervention: Dinitrochlorobenzene (DNCB) and nickel exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthralin exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction of sensitization to DNCB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31351901

Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training (IG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional eccentric training (CG)
Number of subjects: 30
Study: 30005744

Group type: EXPERIMENTAL
Intervention: Midodrine (2.5 mg twice a day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg twice a day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined treatment of midodrine and pyridostigmine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Classic OH (control group, n=87)
Number of subjects: 17
Study: 27028612

Group type: EXPERIMENTAL
Intervention: Power training (25-30 sessions over 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period (10 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detraining (10 weeks follow-up after training)
Number of subjects: 0
Study: 25007091

Group type: EXPERIMENTAL
Intervention: pSG2.HIVconsv DNA vaccine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv vaccine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv vaccine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ChAdV-63
Number of subjects: 32
Study: 22311342

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 19931416

Group type: EXPERIMENTAL
Intervention: IRSCE at 14.0 g (7.8 g of inulin)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: IRSCE at 8.1 g/d (5.0 g of inulin)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (sucrose 10 g and 8.1 g/d)
Number of subjects: 53
Study: 17550987

Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 147
Study: 19223885

Group type: EXPERIMENTAL
Intervention: Pico-Salax plus bisacodyl
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Pico-Salax alone
Number of subjects: 315

Group type: COMPARATOR
Intervention: Oral sodium phosphate
Number of subjects: 315
Study: 15177801

Group type: EXPERIMENTAL
Intervention: Targets presented to the same visual field (VF)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Targets presented to different visual fields (VFs)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Second target presented to the right hemisphere (RH)
Number of subjects: 1
Study: 11494545

Group type: EXPERIMENTAL
Intervention: IFN-ribavirin combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN monotherapy
Number of subjects: 0
Study: 9470077

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (SB) 400 micrograms every 4 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inhaled salmeterol (SM) 100 micrograms every 12 hours
Number of subjects: 19
Study: 8271352

Group type: EXPERIMENTAL
Intervention: Standard carbohydrate-based TPN (8.5% amino acids, 50% dextrose, 7.5% of total calories from lipids)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Isocaloric lipid-based TPN (8.5% amino acids, 30% dextrose, 40% of total calories from lipids)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Standard carbohydrate-based TPN (CHO)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Isocaloric lipid-based TPN (LIP-CHO)
Number of subjects: 43
Study: 3103415

Group type: EXPERIMENTAL
Intervention: sweet acidophilus milk (SAM) made with sonicated cells
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: yogurt
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: heated yogurt
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: yogurt plus lactose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: heated yogurt plus lactase
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: milk
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: sweet acidophilus milk (SAM)
Number of subjects: 14
Study: 31361019

Group type: EXPERIMENTAL
Intervention: NKTR-181 (100-600 mg BID)
Number of subjects: 638
Study: 29584536

Group type: EXPERIMENTAL
Intervention: RTclin test on days 1, 2, 3, 7, and 60
Number of subjects: 112

Group type: COMPARATOR
Intervention: RTclin test on days 1 and 60
Number of subjects: 112
Study: 28784179

Group type: EXPERIMENTAL
Intervention: Social skills training (n=10 CCS), bi-weekly sessions over 8 months covering making social contacts, problem solving, emotional self-regulation, emotional expression and recognition.
Number of subjects: 362

Group type: COMPARATOR
Intervention: Waiting list control group (n=9 CCS).
Number of subjects: 362
Study: 25705899

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25488448

Group type: EXPERIMENTAL
Intervention: Vitamin D deficient (<12 ng/ml)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient (12 to <20 ng/ml)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Vitamin D sufficient (≥ 20 ng/ml)
Number of subjects: 266
Study: 22974257

Group type: EXPERIMENTAL
Intervention: Psychosomatic consultation in the workplace
Number of subjects: 280

Group type: COMPARATOR
Intervention: Conventional regional outpatient clinic care
Number of subjects: 280
Study: 19323613

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine ER 30 mg
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine ER 15 mg
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine immediate release (CIR) 10 mg
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 17716961

Group type: EXPERIMENTAL
Intervention: Intrauterine surgery for repair of fetal myelomeningocele
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open repair through a hysterotomy
Number of subjects: 0
Study: 15050506

Group type: EXPERIMENTAL
Intervention: Dragon boat training for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary control subjects
Number of subjects: 0
Study: 11304861

Group type: EXPERIMENTAL
Intervention: Combination of estriol (1 mg/d) and pelvic floor muscle exercise (PFME)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pelvic floor muscle exercise (PFME) alone
Number of subjects: 66
Study: 9398099

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7955242

Group type: EXPERIMENTAL
Intervention: Group B (1990 to 1993) with 'no touch' technique, antegrade and retrograde blood cardioplegia, single aortic cross-clamp
Number of subjects: 131

Group type: COMPARATOR
Intervention: Group A (1988 to 1989) with standard techniques
Number of subjects: 131
Study: 3115138

Group type: EXPERIMENTAL
Intervention: Intrathecal buprenorphine (0.15 mg) plus 20 mg tetracaine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (20 mg tetracaine only)
Number of subjects: 29
Study: 28736918

Group type: EXPERIMENTAL
Intervention: Erenumab (AMG 334), single doses ranging from 1 mg to 70 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erenumab (AMG 334), multiple doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erenumab (AMG 334)
Number of subjects: 0
Study: 25832556

Group type: EXPERIMENTAL
Intervention: Early oral feeding (n=44)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Late oral feeding (n=45)
Number of subjects: 89
Study: 24834772

Group type: EXPERIMENTAL
Intervention: SIT (Allergen-specific immunotherapy)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pharmacological treatment (Control)
Number of subjects: 29
Study: 22808958

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (40 children)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (15 children)
Number of subjects: 55
Study: 20577073

Group type: EXPERIMENTAL
Intervention: Clavicle ORIF
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 132
Study: 18392659

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted APR
Number of subjects: 99

Group type: COMPARATOR
Intervention: Open APR
Number of subjects: 99
Study: 16012002

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PcV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12101110

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg daily)
Number of subjects: 1312
Study: 10577401

Group type: EXPERIMENTAL
Intervention: Emergency medical services (EMS) personnel
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Laypersons
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: EMS personnel
Number of subjects: 261
Study: 8527571

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2125547

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (starting at 50 mg for 3 days, increasing to 100 mg for 3 days, then up to 150 mg daily if necessary)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Imipramine (starting at 50 mg for 3 days, increasing to 100 mg for 3 days, then up to 150 mg daily if necessary)
Number of subjects: 20
Study: 7010892

Group type: EXPERIMENTAL
Intervention: Gentamicin beads
Number of subjects: 48

Group type: COMPARATOR
Intervention: Suction-irrigation drainage
Number of subjects: 48
Study: 30500558

Group type: EXPERIMENTAL
Intervention: Enhanced Monitoring arm
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Lifestyle arm
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 286
Study: 29466111

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25892374

Group type: EXPERIMENTAL
Intervention: Cervical extensor endurance test (CEET)
Number of subjects: 30
Study: 24093935

Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Operative laparoscopy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 96
Study: 22247932

Group type: EXPERIMENTAL
Intervention: Tonic painful mechanical stimulation applied to pericranial muscles by a mechanical headband pressure device at VAS5 intensity for 10 minutes
Number of subjects: 40
Study: 19190104

Group type: EXPERIMENTAL
Intervention: Continuous sc insulin and pramlintide infusion (part B)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Continuous sc insulin monotherapy (part A)
Number of subjects: 13
Study: 17933161

Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 106

Group type: COMPARATOR
Intervention: CTrach
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 106
Study: 15328305

Group type: EXPERIMENTAL
Intervention: Resistance training (leg-extension and leg-press exercises, 3 times per week for 14 weeks)
Number of subjects: 9
Study: 11157331

Group type: EXPERIMENTAL
Intervention: Standard preoperative and postoperative tube feeding
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Arginine-supplemented preoperative and postoperative tube feeding
Number of subjects: 49

Group type: COMPARATOR
Intervention: No preoperative and standard postoperative tube feeding (Control)
Number of subjects: 49
Study: 9726693

Group type: EXPERIMENTAL
Intervention: 200 mg dexibuprofen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 mg dexibuprofen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both dexibuprofen preparations
Number of subjects: 16
Study: 7642184

Group type: EXPERIMENTAL
Intervention: Laser-induced temporary scotoma (argon laser exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Background complexity and target contrast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target motion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast
Number of subjects: 0
Study: 2651132

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 330292

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide benzoyl-beta-amino-isobutyrate (TBI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Betamethasone dipropionate
Number of subjects: 21
Study: 30260294

Group type: EXPERIMENTAL
Intervention: JNJ-54175446 (doses ranging from 0.5 to 600 mg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 27455573

Group type: EXPERIMENTAL
Intervention: Remaxol (single daily intravenous administration, 400 mL at 3-4 mL/min rate) for 3-5 days after thrombolytic therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional thrombolytic therapy
Number of subjects: 126
Study: 25514391

Group type: EXPERIMENTAL
Intervention: Low glycemic index multi-nutrient supplement (breakfast replacement)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal breakfast (control group)
Number of subjects: 71
Study: 22083390

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Conventional vocational training
Number of subjects: 312
Study: 20123859

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intervention (before CPAP therapy)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy after 3 months
Number of subjects: 32
Study: 18590203

Group type: EXPERIMENTAL
Intervention: Tongyouqing
Number of subjects: 58

Group type: COMPARATOR
Intervention: tijiaseluo (6 mg, qd)
Number of subjects: 58